Cardiovasc Prev Pharmacother.  2025 Jan;7(1):1-8. 10.36011/cpp.2025.7.e2.

Nonalcoholic fatty liver disease and heart failure with preserved ejection fraction: a focus on risk factors and management

• Lee J
• Shin MS

• KMID: 2564010
• DOI: http://doi.org/10.36011/cpp.2025.7.e2

Abstract

Nonalcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) are two increasingly prevalent conditions that share common risk factors, including obesity, diabetes, and aging. NAFLD, marked by hepatic steatosis, is a leading cause of liver disease globally, with cardiovascular disease accounting for most deaths among those affected. HFpEF, characterized by diastolic dysfunction and systemic inflammation, accounts for a growing share of heart failure cases, especially among older adults. The bidirectional relationship between NAFLD and HFpEF involves shared mechanisms such as systemic inflammation, insulin resistance, and metabolic dysfunction. These overlapping processes create a vicious cycle that exacerbates each condition. This review emphasizes the shared pathophysiology, risk factors, and management strategies for these interconnected diseases. Promising interventions, including exercise, weight loss, and emerging pharmacological treatments like sodium-glucose cotransporter 2 inhibitors, are effective in addressing both NAFLD and HFpEF. By targeting these common pathways, there is a unique opportunity to develop integrated treatment approaches that could improve outcomes for affected patients.

Keyword

Nonalcoholic fatty liver disease; Nonalcoholic fatty liver disease; Heart failure; Risk factors; Therapeutics

Reference

1. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020; 41:bnz009. DOI: 10.1210/endrev/bnz009. PMID: 31629366.

2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64:73–84. DOI: 10.1002/hep.28431. PMID: 26707365.

3. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9:524–30. DOI: 10.4016/32826.01. PMID: 21440669.

4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77:1335–47. DOI: 10.1097/hep.0000000000000004. PMID: 36626630.

5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78:1966–86. DOI: 10.1097/HEP.0000000000000520. PMID: 37363821.

6. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47–64. DOI: 10.1016/j.jhep.2014.12.012. PMID: 25920090.

7. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24:908–22. DOI: 10.1038/s41591-018-0104-9. PMID: 29967350.

8. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016; 65:589–600. DOI: 10.1016/j.jhep.2016.05.013. PMID: 27212244.

9. Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart. 2022; 108:1351–60. DOI: 10.1136/heartjnl-2021-320131. PMID: 35042750.

10. Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, et al. Heart disease and stroke statistics: 2023 update: a report from the American Heart Association. Circulation. 2023; 147:e93–621. DOI: 10.1161/CIR.0000000000001123. PMID: 36695182.

11. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79:e263–421. DOI: 10.1161/CIR.0000000000001063. PMID: 35363499.

12. Magana-Serrano JA, Almahmeed W, Gomez E, Al-Shamiri M, Adgar D, Sosner P, et al. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (identification of patients with heart failure and preserved systolic function: an epidemiological regional study). Am J Cardiol. 2011; 108:1289–96. DOI: 10.1016/j.amjcard.2011.06.044. PMID: 22000627.

13. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32:670–9. DOI: 10.1093/eurheartj/ehq426. PMID: 21138935.

14. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018; 6:678–85. DOI: 10.1016/j.jchf.2018.03.006. PMID: 30007560.

15. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014; 64:2281–93. DOI: 10.1016/j.jacc.2014.08.036. PMID: 25456761.

16. Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, et al. Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries. J Am Heart Assoc. 2021; 10:e021654. DOI: 10.1161/jaha.121.021654. PMID: 34755544.

17. Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2023; 72:372–80. DOI: 10.1136/gutjnl-2022-327672. PMID: 35879047.

18. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7:851–61. DOI: 10.1016/s2468-1253(22)00165-0. PMID: 35798021.

19. Huh Y, Cho YJ, Nam GE. Recent epidemiology and risk factors of nonalcoholic fatty liver disease. J Obes Metab Syndr. 2022; 31:17–27. DOI: 10.7570/jomes22021. PMID: 35332111.

20. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64:1388–402. DOI: 10.1016/j.jhep.2015.11.004. PMID: 27062661.

21. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology. 2015; 149:1784–93. DOI: 10.1053/j.gastro.2015.08.011. PMID: 26299412.

22. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115:1343–51. DOI: 10.1172/jci200523621. PMID: 15864352.

23. Meex RC, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017; 13:509–20. DOI: 10.1038/nrendo.2017.56. PMID: 28621339.

24. Song Z, Xiaoli AM, Yang F. Regulation and metabolic significance of de novo lipogenesis in adipose tissues. Nutrients. 2018; 10:1383. DOI: 10.3390/nu10101383. PMID: 30274245.

25. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22:63. DOI: 10.1186/s12902-022-00980-1. PMID: 35287643.

26. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120:1183–92. DOI: 10.1053/gast.2001.23256. PMID: 11266382.

27. Koo DJ, Lee WY. The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence? Cardiovasc Prev Pharmacother. 2022; 4:132–41. DOI: 10.36011/cpp.2022.4.e17.

28. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021; 23:352–80. DOI: 10.1002/ejhf.2115. PMID: 33605000.

29. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017; 70:2476–86. DOI: 10.3410/f.732122496.793539767. PMID: 29141781.

30. Nair N. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. Rev Cardiovasc Med. 2020; 21:531–40. DOI: 10.31083/j.rcm.2020.04.154. PMID: 33387998.

31. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42:3599–726. DOI: 10.15829/1560-4071-2023-5168. PMID: 34447992.

32. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023; 329:827–38. DOI: 10.1001/jama.2023.2020. PMID: 36917048.

33. Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024; 403:1083–92. DOI: 10.1016/s0140-6736(23)02756-3. PMID: 38367642.

34. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011; 4:324–31. DOI: 10.1161/circheartfailure.110.959890. PMID: 21350053.

35. Jung MH, Shin MS. Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. Korean J Intern Med. 2023; 38:157–66. DOI: 10.3904/kjim.2022.271. PMID: 36740840.

36. Ho JE, Enserro D, Brouwers FP, Kizer JR, Shah SJ, Psaty BM, et al. Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016; 9:e003116. DOI: 10.1161/CIRCHEARTFAILURE.115.003116. PMID: 27266854.

37. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, et al. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017; 69:1129–42. DOI: 10.1016/j.jacc.2016.11.081. PMID: 28254175.

38. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482:179–85. DOI: 10.1038/nature10809. PMID: 22297845.

39. Lee MP, Glynn RJ, Schneeweiss S, Lin KJ, Patorno E, Barberio J, et al. Risk factors for heart failure with preserved or reduced ejection fraction among Medicare beneficiaries: application of competing risks analysis and gradient boosted model. Clin Epidemiol. 2020; 12:607–16. DOI: 10.2147/clep.s253612. PMID: 32606986.

40. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016; 134:73–90. DOI: 10.1161/circulationaha.116.021884. PMID: 27358439.

41. Capone F, Vettor R, Schiattarella GG. Cardiometabolic HFpEF: NASH of the heart. Circulation. 2023; 147:451–3. DOI: 10.1161/circulationaha.122.062874. PMID: 36745698.

42. VanWagner LB, Wilcox JE, Ning H, Lewis CE, Carr JJ, Rinella ME, et al. Longitudinal association of non-alcoholic fatty liver disease with changes in myocardial structure and function: the CARDIA Study. J Am Heart Assoc. 2020; 9:e014279. DOI: 10.1161/jaha.119.014279. PMID: 32067588.

43. Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020; 10:12440. DOI: 10.1038/s41598-020-69013-y. PMID: 32709942.

44. Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review. World J Gastroenterol. 2016; 22:6318–27. DOI: 10.3748/wjg.v22.i27.6318. PMID: 27468220.

45. Sachdev V, Sharma K, Keteyian SJ, Alcain CF, Desvigne-Nickens P, Fleg JL, et al. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2023; 147:e699–715. DOI: 10.1161/cir.0000000000001122. PMID: 36943925.

46. Crisci G, De Luca M, D’Assante R, Ranieri B, D’Agostino A, Valente V, et al. Effects of exercise on heart failure with preserved ejection fraction: an updated review of literature. J Cardiovasc Dev Dis. 2022; 9:241. DOI: 10.3390/jcdd9080241. PMID: 36005405.

47. Finer N. Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes. Diabetes Obes Metab. 2022; 24 Suppl 2:44–54. DOI: 10.1111/dom.14569. PMID: 34622555.

48. El Hajj EC, El Hajj MC, Sykes B, Lamicq M, Zile MR, Malcolm R, et al. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc. 2021; 10:e022930. DOI: 10.1161/jaha.121.022930. PMID: 34713711.

49. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008; 6:1396–402. DOI: 10.1016/j.cgh.2008.08.012. PMID: 18986848.

50. Mikhalkova D, Holman SR, Jiang H, Saghir M, Novak E, Coggan AR, et al. Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction. Obesity (Silver Spring). 2018; 26:284–90. DOI: 10.1002/oby.22038. PMID: 29243396.

51. Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, et al. Bariatric surgery in patients with non-alcoholic fatty liver disease: from pathophysiology to clinical effects. World J Hepatol. 2019; 11:138–49. DOI: 10.4254/wjh.v11.i2.138. PMID: 30820265.

52. Euh W, Lim S, Kim JW. Sodium-glucose cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021; 12:613389. DOI: 10.3389/fendo.2021.613389. PMID: 34177796.

53. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018; 41:1801–8. DOI: 10.2337/dc18-0165. PMID: 29895557.

54. Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020; 46:427–41. DOI: 10.1016/j.diabet.2019.12.007. PMID: 31923578.

55. Sinha B, Datta D, Ghosal S. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes. JGH Open. 2020; 5:219–27. DOI: 10.1002/jgh3.12473. PMID: 33553659.

56. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385:1451–61. DOI: 10.1056/NEJMoa2107038. PMID: 34449189.

57. Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022; 23:3107. DOI: 10.3390/ijms23063107. PMID: 35328527.

58. Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021; 15:827–40. DOI: 10.5009/gnl20367. PMID: 33820884.

59. Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes. 2017; 9:800–9. DOI: 10.1111/1753-0407.12555. PMID: 28332301.

60. Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020; 19:124. DOI: 10.1186/s12933-020-01100-w. PMID: 32758236.

61. Doumas M, Imprialos K, Dimakopoulou A, Stavropoulos K, Binas A, Athyros VG. The role of statins in the management of nonalcoholic fatty liver disease. Curr Pharm Des. 2018; 24:4587–92. DOI: 10.2174/1381612825666190117114305. PMID: 30652643.

62. Marume K, Takashio S, Nagai T, Tsujita K, Saito Y, Yoshikawa T, et al. Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease: report from the JASPER Study. Circ J. 2019; 83:357–67. DOI: 10.1253/circj.cj-18-0639. PMID: 30416189.

63. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med 2024 Nov 17 [Epub]. https://doi.org/10.1038/s41591-024-03374-z. DOI: 10.1038/s41591-024-03374-z. PMID: 39551891.

64. Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity. Circulation 2024 Nov 18 [Epub]. https://doi.org/10.1161/CIRCULATIONAHA.124.072679. DOI: 10.1161/CIRCULATIONAHA.124.072679. PMID: 39556714.

65. Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR Substudy. J Am Coll Cardiol 2024 Nov 5 [Epub]. https://doi.org/10.1016/j.jacc.2024.11.001. DOI: 10.1016/j.jacc.2024.11.001. PMID: 39566869.

66. Shin J, Kim R, Kim HS. Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice. Cardiovasc Prev Pharmacother. 2023; 5:49–53. DOI: 10.36011/cpp.2023.5.e7.

67. Lee HA, Kim HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci. 2023; 24:9324. DOI: 10.3390/ijms24119324. PMID: 37298276.

68. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024; 391:299–310. DOI: 10.1056/nejmoa2401943. PMID: 38856224.

69. Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024; 391:311–9. DOI: 10.1056/nejmoa2401755. PMID: 38847460.